Matsushita Maiko, Kawaguchi Mai
Division of Clinical Physiology and Therapeutics, Keio University, Faculty of Pharmacy, 1-5-30, Shiabakoen, Minato-Ku, Tokyo, Japan.
J Oncol. 2018 Oct 25;2018:8653489. doi: 10.1155/2018/8653489. eCollection 2018.
Recent advances in cancer immunotherapy, including immune checkpoint inhibitors or adoptive T cell therapies, have contributed to better outcomes in cancer patients. However, there are still many cancers with no cure. Therefore, combinations of several treatment strategies are being explored, and enhancing anticancer immunity will play an important role to combat the disease. There have been several reports on the immune-modulatory effects of commonly used drugs, namely, statin, metformin, and angiotensin receptor blockers (ARBs), which suggest that these drugs could enhance immunity against cancer cells. Other anticancer drugs, such as anthracyclines, thalidomides, lenalidomides, and hypomethylating drugs, could also strengthen the immune system to attack cancer cells at a relatively low dose. Hence, these drugs might contribute to better outcomes in cancer patients.
癌症免疫疗法的最新进展，包括免疫检查点抑制剂或过继性T细胞疗法，已使癌症患者取得了更好的治疗效果。然而，仍有许多癌症无法治愈。因此，人们正在探索多种治疗策略的联合使用，增强抗癌免疫力将在对抗该疾病中发挥重要作用。已有多篇关于常用药物（即他汀类药物、二甲双胍和血管紧张素受体阻滞剂）免疫调节作用的报道，这些报道表明这些药物可增强针对癌细胞的免疫力。其他抗癌药物，如蒽环类药物、沙利度胺、来那度胺和去甲基化药物，也可在相对低剂量时增强免疫系统对癌细胞的攻击。因此，这些药物可能有助于癌症患者取得更好的治疗效果。
